Embedded Files
By 2026, global hepatocellular carcinoma (HCC) incidence is projected to exceed 1 million new cases annually. While HCC is a leading cause of cancer deaths worldwide, its frequency map varies significantly by region.
By 2026, global hepatocellular carcinoma (HCC) incidence is projected to exceed 1 million new cases annually. While HCC is a leading cause of cancer deaths worldwide, its frequency map varies significantly by region.
Globally, the crude rate and ASIR for liver cancer stood at 11.6 and 5.2 per 100,000 population, respectively. (Q Guo · 2024 ) . Current estimate: The global crude rate for liver cancer is estimated at approximately 13.0 to 14.0 per 100,000 people. This figure is rising faster than the ASIR because the global population is growing and, more importantly, aging. Since liver cancer is more common in the elderly, the absolute number of cases per 100,000 inhabitants in the total population is increasing.
According to the International Agency for Research on Cancer (IARC), the global ASIR for liver cancer is approximately 9.5 per 100,000 person-years.
• Gender differences: This average masks a large gap:
o Men: Approximately 13.0 to 14.0 per 100,000.
o Women: Approximately 5.0 to 6.0 per 100,000
Models for 2026 or 2027 must take the "metabolic shift" into account. Although Hepatitis B vaccinations reduce the incidence in younger cohorts, the rise in MASLD (metabolic fatty liver disease) and alcohol consumption in the US and Europe means that incidence rates in those regions are not decreasing, but are instead stabilizing or rising slightly.
HCC risk factors are parallel to sustained liver injury risk factors, i.e., hepatitis B and C, excessive alcohol intake resulting in alcoholic liver disease, lifestyle patterns, and pathological processes leading to non-alcoholic liver disease, among others.
Despite recent great improvements in liver cancer therapeutics such as surgery, chemotherapy, and immunotherapy, this disease remains highly lethal due to its aggressive metastases. Evidence points to the ability of solid tumors to develop multiple invasion and resistance pathways that allow them to circumvent inhibition by a single signaling pathway. In the specific case of HCC, at the time of diagnosis, tumors may be too large or may have encroached on nearby major blood vessels or metastasized, rendering most HCC patients unsuitable candidates for surgical resection.
Identification of factors associated with proliferation in the hepatocellular carcinoma (HCC) micro-environment aids in understanding the mechanisms of disease progression and provides druggable targets. Gene expression profiles of individual cells in HCC and para-carcinoma tissues can be effectively obtained using the single-cell RNA sequencing (scRNA-Seq) technique.
A global frequency map of hepatocellular carcinoma (HCC) incidence in 2026 could show the highest rates in East Asia and Africa, with rising rates in the United States and Europe. While rates in East Asia and Africa may be influenced by chronic viral hepatitis (HBV and HCV), the rising rates in the US and Europe are increasingly linked to non-alcoholic steatohepatitis (NASH).
Projections indicate that globally, there will be over a million cases of liver cancer annually, with hepatocellular carcinoma (HCC) accounting for 75-85% of these cases. The most common causes of HCC globally include HBV, HCV, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). While HBV infection is a leading cause, NASH is becoming a growing concern.Maintenance of proliferative signaling is a hallmark of cancer. Healthy tissues carefully control their cell growth and division cycle and ensure cell number homeostasis, which preserves tissue architecture and function. Cancer cells emit sustained proliferative signals that activate progression of the cell cycle as well as support the formation and growth of tumor tissue. Although the liver is susceptible to cancer invasion, it is also an organ with the capacity to regenerate after surgical removal or chemical injury. The regenerative process of a normal,healthy liver is predominantly dependent on hepatocyte proliferation, growth, and programmed cell death. The ability to distinguish proliferative hepatocytes from hepatocellular carcinoma (HCC) and normal liver tissues and comparison of their gene expression profiles will aid in understanding the mechanisms underlying aberrant proliferative signaling in malignant cells.
In silico analysis suggests disruption of interactions between HAMP from hepatocytes and SLC40A1 from macrophages in hepatocellular carcinoma. Research shows that HAMP was significantly downregulated in malignant hepatocytes. In addition, a subset of macrophages expressing SLC40A1 and genes reacting to various infections was absent in HCC tissue. These findings support the involvement of HAMP-SLC40A1 signaling in aberrant hepatocyte proliferation in the HCC microenvironment.
Chemotherapy only leads to moderate improvement of the overall survival of patients, due to its lack of specificity as well as the side effects that are often induced as a result of their significant toxicity. Thus, limitations in HCC treatment result in a poor prognosis, and resistance to traditional radiotherapy and chemotherapies. Unfortunately, patients with advanced HCC have a median overall survival below 1 year, and the 5-year recurrence rate of HCC is as high as 70%. The same results (i.e., little effect of chemotherapy, poor prognosis, and treatment resistance) can be seen in other less common types of liver cancers.
Prognosis of Risk Factors for Liver Diseases (2026–2040)
Prognosis of Risk Factors for Liver Diseases (2026–2040)
The table below shows the expected trends in mortality and incidence for the major risk factors, based on global projections up to 2040:
Risk Factor Trend to 2040 Key Findings
MASLD / MASH 📈 Strongly Rising The incidence of MASLD-related liver cancer is expected to rise by 19% per year. By 2040, more than 55% of adults will have MASLD.
Hepatitis B (HBV) 📉 Stable / Declining The mortality rate from HBV-related liver cancer will remain relatively stable or decline slightly until 2040 due to improved screening and vaccination.
Alcohol (ALD) 📈 Rising Alcohol remains a major factor; the proportion of liver cancer cases due to alcohol is expected to rise from 18.8% (2022) to 21.1% (2050). Hepatitis C (HCV) 📉 Sharply Declining Due to effective antiviral drugs (DAAs), HCV-related mortality is expected to be marginal by 2034.
MASLD/MASH (Metabolic factors): This is the fastest-growing cause of liver cancer (HCC) and liver cirrhosis worldwide. In countries such as the US, MASLD is expected to be the leading reason for liver transplants by 2040.
Hepatitis B (HBV): Although the total number of cases remains stable, the burden is shifting to the older population (65+), where mortality rates due to previous chronic infections may rise slightly before declining.
Alcohol-related liver disease (ALD): ALD is expected to overtake HCV as the leading cause of death from liver cancer around 2026, followed shortly thereafter by MASLD.
Page updated
Google Sites
Report abuse